MA27746A1 - Vaccins - Google Patents

Vaccins

Info

Publication number
MA27746A1
MA27746A1 MA28489A MA28489A MA27746A1 MA 27746 A1 MA27746 A1 MA 27746A1 MA 28489 A MA28489 A MA 28489A MA 28489 A MA28489 A MA 28489A MA 27746 A1 MA27746 A1 MA 27746A1
Authority
MA
Morocco
Prior art keywords
muc
relates
vaccines
recombinant
dnas
Prior art date
Application number
MA28489A
Other languages
English (en)
Inventor
Paul Andrew Hamblin
Del Cura Maria De Los An Rocha
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27746A1 publication Critical patent/MA27746A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouveaux ADN MUC-1 recombinés, qui présentent une homologie réduite avec le MUC-1 naturel. L'invention concerne également des compositions pharmaceutiques contenant de tels MUC-1 recombinés.
MA28489A 2003-02-28 2005-09-09 Vaccins MA27746A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0304634.9A GB0304634D0 (en) 2003-02-28 2003-02-28 Vaccines

Publications (1)

Publication Number Publication Date
MA27746A1 true MA27746A1 (fr) 2006-02-01

Family

ID=9953871

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28489A MA27746A1 (fr) 2003-02-28 2005-09-09 Vaccins

Country Status (18)

Country Link
US (1) US20060147458A1 (fr)
EP (1) EP1597368A2 (fr)
JP (1) JP2007524352A (fr)
KR (1) KR20050107472A (fr)
CN (1) CN1753994A (fr)
AU (1) AU2004215187A1 (fr)
BR (1) BRPI0407601A (fr)
CA (1) CA2517062A1 (fr)
CO (1) CO5670372A2 (fr)
GB (1) GB0304634D0 (fr)
IS (1) IS7956A (fr)
MA (1) MA27746A1 (fr)
MX (1) MXPA05009160A (fr)
NO (1) NO20054102L (fr)
PL (1) PL378761A1 (fr)
RU (1) RU2005125608A (fr)
WO (1) WO2004076665A2 (fr)
ZA (1) ZA200506548B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0617387D0 (en) * 2006-09-04 2006-10-11 Glaxo Group Ltd Synthetic gene
CN103570821A (zh) * 2012-07-27 2014-02-12 北京智飞绿竹生物制药有限公司 粘蛋白-1抗原性多肽及其作为肿瘤疫苗的用途
CN110198733B (zh) 2016-09-28 2024-04-30 巴法里安诺迪克有限公司 用于增强痘病毒中转基因的稳定性的组合物和方法
CN113321724B (zh) * 2021-03-24 2022-02-01 深圳市新靶向生物科技有限公司 一种与食道癌驱动基因突变相关的抗原肽及其应用
US20250057946A1 (en) * 2021-12-20 2025-02-20 Zoetis Services Llc Use of interferon as an adjuvant in vaccines
CN116535488A (zh) * 2023-04-17 2023-08-04 北京世纪沃德生物科技有限公司 一种重组kl-6质控品蛋白及其质控品和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2383737C (fr) * 1999-09-08 2011-01-18 Transgene S.A. Peptides derives de muc-1
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0321614D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Vaccines

Also Published As

Publication number Publication date
CN1753994A (zh) 2006-03-29
ZA200506548B (en) 2007-12-27
NO20054102L (no) 2005-09-27
US20060147458A1 (en) 2006-07-06
AU2004215187A1 (en) 2004-09-10
CO5670372A2 (es) 2006-08-31
EP1597368A2 (fr) 2005-11-23
MXPA05009160A (es) 2005-10-20
NO20054102D0 (no) 2005-09-02
JP2007524352A (ja) 2007-08-30
PL378761A1 (pl) 2006-05-15
CA2517062A1 (fr) 2004-09-10
RU2005125608A (ru) 2006-03-27
KR20050107472A (ko) 2005-11-11
IS7956A (is) 2005-07-25
BRPI0407601A (pt) 2006-02-14
WO2004076665A2 (fr) 2004-09-10
GB0304634D0 (en) 2003-04-02
WO2004076665A3 (fr) 2005-02-24

Similar Documents

Publication Publication Date Title
MA29413B1 (fr) Combinaisons de substances actives
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
WO2003103603A3 (fr) Nouveau sel de type formiate de o-desmethylvenlafaxine
DE60228219D1 (de) Spiritusbrenner
AR032231A1 (es) Nuevas proteinas insecticidas de bacillus thuringiensis
MA30581B1 (fr) Vaccin viral recombinant
EP1649006A4 (fr) Polypeptides d'amylase exospecifiques, acides nucleiques codant lesdits polypeptides et leurs utilisations
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
WO2004024757A3 (fr) Molecules pna modifiées
WO2003015697A3 (fr) Mutants d'interleukine-2 a toxicite reduite
EP1423510A4 (fr) Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
MA29459B1 (fr) Vaccins
WO2005030259A3 (fr) Conjugues lipophiles d'acides nucleiques
TW200612945A (en) Aerosol suspension formulations containing TG 227 ea as propellant
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
EP1988099A3 (fr) Protéines insecticides de Bacillus thuringiensis
AU8738401A (en) Novel kallikrein gene
EA200600403A1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
WO2001072125A8 (fr) Combinaisons de principes actifs ayant des proprietes insecticides et acaricides
MXPA03009478A (es) Mezclas con resistencia al impacto modificada de poli (tereftalato de etileno) y al menos un policarbonato basado en dihidroxidiarilciclohexano.
ATE473283T1 (de) Dna-expressionsvektoren
MA27746A1 (fr) Vaccins
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists